Diagnosing Alopecia Areata: Differential Diagnosis, Comorbidities, and Disease Burden

In this episode, 'Diagnosing Alopecia Areata: Differential Diagnosis, Comorbidities, and Disease Burden,' the expert dermatologist explored the following questions:

Describe the clinical, economic, and psychosocial burden that patients with alopecia areata (AA) may experience.

What is in the differential diagnosis for alopecia areata and how is a definitive diagnosis made?

What are the comorbidities associated with alopecia areata?

The panelist examined the wide-ranging burden of alopecia areata on patients and their families, including the challenges of accessing specialist care, navigating prior authorization processes, and the financial strain faced by uninsured or underinsured patients who cannot access the three FDA-approved Janus kinase (JAK) inhibitors now available for this condition. Dr. McMichael highlighted the significant psychosocial toll of the disease, particularly for children and women, including social withdrawal, depression, and impaired professional and social functioning, as well as the day-to-day burden of being misunderstood by others in public settings. Turning to differential diagnosis, she noted that alopecia areata is frequently misdiagnosed — especially in younger patients who may be incorrectly treated for tinea capitis — and that delayed treatment has been associated with poorer outcomes in JAK inhibitor trials, underscoring the importance of early referral to a board-certified dermatologist. She also outlined the broad range of comorbidities associated with alopecia areata, including atopic dermatitis, vitiligo, rheumatoid arthritis, multiple sclerosis, and diabetes, emphasizing the need for a thorough patient history and holistic approach to care.

Throughout the conversation, the expert provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'Beyond the SALT Score: Evaluating Alopecia Areata More Holistically,' features the panelists advancing their conversation on alopecia areata and focusing on the Scalp Area and Hair Loss Tool (SALT) scoring system, its strengths and limitations, and a novel scoring framework developed to more comprehensively capture disease severity beyond scalp involvement alone.